This document provides brief biographies of six panelists:
- Glen Doucet is Vice President of Advocacy at Canadian Pharmacists Association with over 23 years of experience in government relations.
- Louise Binder is a health advocate and lawyer who has worked to improve access to HIV/AIDS and cancer treatments for over 20 years.
- Marc-André Gagnon is an Associate Professor researching political economy of pharmaceutical sector including regulatory capture and innovation policy.
- Don Husereau is an Adjunct Professor focusing on evidence-based health policy and economics and chairs health technology assessment standards groups.
- W. Neil Palmer is president of a leading pricing and reimbursement consultancy and adjunct professor teaching on
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
Insights will be provided by a panel of representatives from other chronic disease patient advocacy organizations who will discuss how they interact with health systems, successfully advocate, and help each other through the ongoing journey of dealing with a chronic illness.
Contact the presenters:
●
●
●
View the video: https://youtu.be/QIQKAUmuEJA
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A review of the responses from each of the federal political parties received by CCSN to its federal election questionnaire.
● Insights on each party’s health care platform with an emphasis on how those positions might affect cancer care.
● Commentary from two veteran cancer patient advocates: Colleen Savage of the Cancer Advocacy Coalition of Canada and Kathy Barnard of the Save Your Skin Foundation, who will discuss their interpretations of the party positions and what they might mean for patients and the cancer care after the election.
Contact the presenters:
● gjeffcott@3sixtypublicaffairs.com
● colleensavage@rogers.com
● kathysaveyourskin@icloud.com
View the video: https://youtu.be/1BVyYfpnZEQ
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
Webinar Information:
The cancer survivor community knows the statistics about cancer all too well: that nearly half of all Canadians will develop cancer over the course of their lives, and that a quarter of them are forecasted to die from the disease. There are dozens of less prevalent cancer types that face significant and different challenges in terms of organization, research and support. The prognosis for many rare cancers is improving as new treatments are developed, however, in Canada, getting access to new therapies and clinical trials is one of many challenges faced by small communities often struggling with the disease and dealing with life’s myriad other challenges.
This webinar will explore what individual caregivers can do, how groups can work together to pool resources and share best practices and information, and provide concrete recommendations for the broader cancer community in Canada. You will learn more about how patients are working with each other, and with the clinical and research community and health systems, to improve the lives of Canadians affected by rare cancers!
Presenters:
• David Josephy, President of GIST Sarcoma Life Raft Group Canada
• Martine Elias, Director of Access, Advocacy & Community Relations with Myeloma Canada
• Durhane Wong-Rieger, President & CEO of the Canadian Organization for Rare Disorders (CORD)
• Bill Dempster, 3Sixty Public Affairs
View the video: https://youtu.be/L3mqpu-iFU0
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
During this webinar, attendees will learn about:
- The role that drug access navigators play in Canada, and why they are needed.
- The challenges drug access navigators face on a daily basis.
- How drug access navigators can help you.
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
Insights will be provided by a panel of representatives from other chronic disease patient advocacy organizations who will discuss how they interact with health systems, successfully advocate, and help each other through the ongoing journey of dealing with a chronic illness.
Contact the presenters:
●
●
●
View the video: https://youtu.be/QIQKAUmuEJA
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A review of the responses from each of the federal political parties received by CCSN to its federal election questionnaire.
● Insights on each party’s health care platform with an emphasis on how those positions might affect cancer care.
● Commentary from two veteran cancer patient advocates: Colleen Savage of the Cancer Advocacy Coalition of Canada and Kathy Barnard of the Save Your Skin Foundation, who will discuss their interpretations of the party positions and what they might mean for patients and the cancer care after the election.
Contact the presenters:
● gjeffcott@3sixtypublicaffairs.com
● colleensavage@rogers.com
● kathysaveyourskin@icloud.com
View the video: https://youtu.be/1BVyYfpnZEQ
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
Webinar Information:
The cancer survivor community knows the statistics about cancer all too well: that nearly half of all Canadians will develop cancer over the course of their lives, and that a quarter of them are forecasted to die from the disease. There are dozens of less prevalent cancer types that face significant and different challenges in terms of organization, research and support. The prognosis for many rare cancers is improving as new treatments are developed, however, in Canada, getting access to new therapies and clinical trials is one of many challenges faced by small communities often struggling with the disease and dealing with life’s myriad other challenges.
This webinar will explore what individual caregivers can do, how groups can work together to pool resources and share best practices and information, and provide concrete recommendations for the broader cancer community in Canada. You will learn more about how patients are working with each other, and with the clinical and research community and health systems, to improve the lives of Canadians affected by rare cancers!
Presenters:
• David Josephy, President of GIST Sarcoma Life Raft Group Canada
• Martine Elias, Director of Access, Advocacy & Community Relations with Myeloma Canada
• Durhane Wong-Rieger, President & CEO of the Canadian Organization for Rare Disorders (CORD)
• Bill Dempster, 3Sixty Public Affairs
View the video: https://youtu.be/L3mqpu-iFU0
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
During this webinar, attendees will learn about:
- The role that drug access navigators play in Canada, and why they are needed.
- The challenges drug access navigators face on a daily basis.
- How drug access navigators can help you.
The Canadian Cancer Survivor Network (CCSN) conducted a survey in April 2013 the discover the impact that being involved in volunteer advocacy and/or the development of public policy has on cancer patients, survivors, caregivers and family members. 51 people completed the survey. Findings were that patient advocacy generally has a positive impact on the self-image of those doing it, that many volunteer advocates felt better, prouder, more useful, more hopeful, more effective and more powerful. Still others felt less angry, less anxious, and less sad. But some survey respondents did feel sadder, angrier, less hopeful and less content. CCSN recommends that organizations ensure that cancer patients involved in advocacy activities receive skills to help them and support to deal with the often slow-moving and sometimes frustrating healthcare, cancer care and government systems in Canada.
In this webinar, our panelists explored ethics, transparency, resources, alignment and conflicts in the important relationships between companies and patient groups.
This webinar presented perspectives from subject matter experts from the innovative medicines industry, governance experts, and patient advocates.
Panelists:
Hugh Scott, Executive Director, Strategic Alliances at Innovative Medicines Canada.
Rosy Sasso, acting Director, Ethics and Compliance at Innovative Medicines Canada.
Brian Huskins, the Senior Fellow of Not-For-Profit Governance at the Institute on Governance.
Martine Elias, Director of Access, Advocacy & Community Relations with Myeloma Canada.
Dr. Durhane Wong-Rieger, PhD, President and CEO of the Canadian Organization for Rare Disorders.
Moderator: Bill Dempster, 3Sixty Public Affairs
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on the Canadian public and private drug access environment
● A moderated panel on the broader access and innovation context, featuring an update on international access to innovative therapies, patient support programs, and innovative pathways for access to treatments
View the video:
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Discussion of the CADTH Symposium
● Recommendations for HTA improvements in Canada
● Audience Q&A
View the video: https://youtu.be/AJCOemf2r6Y
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Deriving more value from real world evidence to ensure timely access of medic...3GDR
Dr Sarah Wamala Andersson, Consultant, Real world evidence and value-based medicines
Pharma Pricing & Market Access Congress 2017 22 February 2017 London
Please share this slideshow with anyone who may be interested!
In this webinar:
● What has prompted the recent re-emergence of public calls for national pharmacare?
● What are Canadian health ministers doing to address this issue?
● What are some potential models for national pharmacare that are under discussion?
Contact the presenters:
● Bill Dempster - wdempster@3sixtypublicaffairs.com
● Gerry Jeffcott - gjeffcott@3sixtypublicaffairs.com
View the video: https://youtu.be/Eh3593x4aoI
Please share these slides with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on how new treatments are reviewed and approved for sale in this country, with a particular emphasis on Health Canada’s regulatory modernization initiative
● Explanation of patient involvement in Health Canada reviews as well as the special access program.
View the video:
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Please share this slideshow with anyone who may be interested!
In this webinar:
● Overview of the structure and operation of Canada’s private drug plan marketplace, including the important distinctions and/or overlaps between private (insurance) and public (government) providers
● Explanation of the role and place of medication coverage within the supplemental health benefits plans of life and health insurance companies which provide pharmaceutical coverage
● Identification of the various providers and influencers which contribute to private formulary (lists of drugs which are covered) decision-making and their roles in the system
● Understanding generally what gets covered, by which plans and under what circumstances and which medications are typically subject to restrictions
● Guidance on how to determine which medications are covered
● Exploration of how patients and caregivers can navigate through the complex private plan system including:
● Who should provide answers regarding coverage and
eligibility?
● What you can do if you run into coverage restrictions / rejections?
● How should patients interact with the private payer community generally?
Contact the presenter:
● suzanne@suzannelepage.ca
● www.suzannelepage.ca
● @suzannelepage
View the video on YouTube: https://youtu.be/yKPUT9Ymj3Y
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
March 2, 2018
Value-based health care is one of the most pressing topics in health care finance and policy today. Value-based payment structures are widely touted as critical to controlling runaway health care costs, but are often difficult for health care entities to incorporate into their existing infrastructures. Because value-based health care initiatives have bipartisan support, it is likely that these programs will continue to play a major role in both the public and private health insurance systems. As such, there is a pressing need to evaluate the implementation of these initiatives thus far and to discuss the direction that American health care financing will take in the coming years.
To explore this important issue, the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School collaborated with Ropes & Gray LLP to host a one-day conference on value-based health care. This event brought together scholars, health law practitioners, and health care entities to evaluate the impact of value-based health care on the American health care system.
For more information, visit our website at: http://petrieflom.law.harvard.edu/events/details/will-value-based-care-save-the-health-care-system
Don't miss our upcoming webinars! Subscribe today.
In this webinar:
1) Attendees will be provided with an overview of the drug approval and reimbursement processes.
2) People will be taken through a review of the updated CADTH patient group/clinician input processes.
3) Everyone will have a better understanding of how the processes are connected and flow into one another.
View the YouTube video here: https://youtu.be/-Bv9DZvSITk
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
In this presentation, Alan Birch discussed the role of an Oncology Drug Access Navigator as well as how the role fits into the healthcare team and what they help patients with. He gave a brief overview and history of the role as well as discussing challenges faced by patients and how National Pharmacare may impact it all.
The webinar was followed by an interactive question & answer session.
About the presenter:
Alan Birch is an Oncology Drug Access Navigator at North York General Hospital. He is a member of ODANO, the oncology drug access navigators of Ontario and has been in the role for the last 5 years. Alan is a registered pharmacy technician by background and is also a member of the Ontario College of Pharmacists and Ontario Pharmacist's Association.
March 02, 2018
Value-based health care is one of the most pressing topics in health care finance and policy today. Value-based payment structures are widely touted as critical to controlling runaway health care costs, but are often difficult for health care entities to incorporate into their existing infrastructures. Because value-based health care initiatives have bipartisan support, it is likely that these programs will continue to play a major role in both the public and private health insurance systems. As such, there is a pressing need to evaluate the implementation of these initiatives thus far and to discuss the direction that American health care financing will take in the coming years.
To explore this important issue, the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School collaborated with Ropes & Gray LLP to host a one-day conference on value-based health care. This event brought together scholars, health law practitioners, and health care entities to evaluate the impact of value-based health care on the American health care system.
For more information, visit our website at: http://petrieflom.law.harvard.edu/events/details/will-value-based-care-save-the-health-care-system
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Takeaways from a roundtable held on June 1st about patient-centred pharmacare in Canada
● Reports from patient groups and other subject matter experts
● A cohesive vision and set of values for national pharmacare in Canada
View the video: https://youtu.be/HMy_gsTDkfI
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
Decision aids help patients and clinicians decide on the best course of treatment, incorporating evidence from systematic reviews, patient values, individual risk factors, and expert recommendations, all in an intuitive and interactive format.
Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...Sardegna Ricerche
L'intervento di Luca Pani (professore Ordinario di Psichiatria Clinica, Università di Miami) in occasione dell'evento "Il valore della ricerca biomedica" che si è tenuto a Pula (CA) il 3 aprile 2019.
The Canadian Cancer Survivor Network (CCSN) conducted a survey in April 2013 the discover the impact that being involved in volunteer advocacy and/or the development of public policy has on cancer patients, survivors, caregivers and family members. 51 people completed the survey. Findings were that patient advocacy generally has a positive impact on the self-image of those doing it, that many volunteer advocates felt better, prouder, more useful, more hopeful, more effective and more powerful. Still others felt less angry, less anxious, and less sad. But some survey respondents did feel sadder, angrier, less hopeful and less content. CCSN recommends that organizations ensure that cancer patients involved in advocacy activities receive skills to help them and support to deal with the often slow-moving and sometimes frustrating healthcare, cancer care and government systems in Canada.
In this webinar, our panelists explored ethics, transparency, resources, alignment and conflicts in the important relationships between companies and patient groups.
This webinar presented perspectives from subject matter experts from the innovative medicines industry, governance experts, and patient advocates.
Panelists:
Hugh Scott, Executive Director, Strategic Alliances at Innovative Medicines Canada.
Rosy Sasso, acting Director, Ethics and Compliance at Innovative Medicines Canada.
Brian Huskins, the Senior Fellow of Not-For-Profit Governance at the Institute on Governance.
Martine Elias, Director of Access, Advocacy & Community Relations with Myeloma Canada.
Dr. Durhane Wong-Rieger, PhD, President and CEO of the Canadian Organization for Rare Disorders.
Moderator: Bill Dempster, 3Sixty Public Affairs
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on the Canadian public and private drug access environment
● A moderated panel on the broader access and innovation context, featuring an update on international access to innovative therapies, patient support programs, and innovative pathways for access to treatments
View the video:
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Discussion of the CADTH Symposium
● Recommendations for HTA improvements in Canada
● Audience Q&A
View the video: https://youtu.be/AJCOemf2r6Y
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Deriving more value from real world evidence to ensure timely access of medic...3GDR
Dr Sarah Wamala Andersson, Consultant, Real world evidence and value-based medicines
Pharma Pricing & Market Access Congress 2017 22 February 2017 London
Please share this slideshow with anyone who may be interested!
In this webinar:
● What has prompted the recent re-emergence of public calls for national pharmacare?
● What are Canadian health ministers doing to address this issue?
● What are some potential models for national pharmacare that are under discussion?
Contact the presenters:
● Bill Dempster - wdempster@3sixtypublicaffairs.com
● Gerry Jeffcott - gjeffcott@3sixtypublicaffairs.com
View the video: https://youtu.be/Eh3593x4aoI
Please share these slides with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on how new treatments are reviewed and approved for sale in this country, with a particular emphasis on Health Canada’s regulatory modernization initiative
● Explanation of patient involvement in Health Canada reviews as well as the special access program.
View the video:
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Please share this slideshow with anyone who may be interested!
In this webinar:
● Overview of the structure and operation of Canada’s private drug plan marketplace, including the important distinctions and/or overlaps between private (insurance) and public (government) providers
● Explanation of the role and place of medication coverage within the supplemental health benefits plans of life and health insurance companies which provide pharmaceutical coverage
● Identification of the various providers and influencers which contribute to private formulary (lists of drugs which are covered) decision-making and their roles in the system
● Understanding generally what gets covered, by which plans and under what circumstances and which medications are typically subject to restrictions
● Guidance on how to determine which medications are covered
● Exploration of how patients and caregivers can navigate through the complex private plan system including:
● Who should provide answers regarding coverage and
eligibility?
● What you can do if you run into coverage restrictions / rejections?
● How should patients interact with the private payer community generally?
Contact the presenter:
● suzanne@suzannelepage.ca
● www.suzannelepage.ca
● @suzannelepage
View the video on YouTube: https://youtu.be/yKPUT9Ymj3Y
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
March 2, 2018
Value-based health care is one of the most pressing topics in health care finance and policy today. Value-based payment structures are widely touted as critical to controlling runaway health care costs, but are often difficult for health care entities to incorporate into their existing infrastructures. Because value-based health care initiatives have bipartisan support, it is likely that these programs will continue to play a major role in both the public and private health insurance systems. As such, there is a pressing need to evaluate the implementation of these initiatives thus far and to discuss the direction that American health care financing will take in the coming years.
To explore this important issue, the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School collaborated with Ropes & Gray LLP to host a one-day conference on value-based health care. This event brought together scholars, health law practitioners, and health care entities to evaluate the impact of value-based health care on the American health care system.
For more information, visit our website at: http://petrieflom.law.harvard.edu/events/details/will-value-based-care-save-the-health-care-system
Don't miss our upcoming webinars! Subscribe today.
In this webinar:
1) Attendees will be provided with an overview of the drug approval and reimbursement processes.
2) People will be taken through a review of the updated CADTH patient group/clinician input processes.
3) Everyone will have a better understanding of how the processes are connected and flow into one another.
View the YouTube video here: https://youtu.be/-Bv9DZvSITk
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
In this presentation, Alan Birch discussed the role of an Oncology Drug Access Navigator as well as how the role fits into the healthcare team and what they help patients with. He gave a brief overview and history of the role as well as discussing challenges faced by patients and how National Pharmacare may impact it all.
The webinar was followed by an interactive question & answer session.
About the presenter:
Alan Birch is an Oncology Drug Access Navigator at North York General Hospital. He is a member of ODANO, the oncology drug access navigators of Ontario and has been in the role for the last 5 years. Alan is a registered pharmacy technician by background and is also a member of the Ontario College of Pharmacists and Ontario Pharmacist's Association.
March 02, 2018
Value-based health care is one of the most pressing topics in health care finance and policy today. Value-based payment structures are widely touted as critical to controlling runaway health care costs, but are often difficult for health care entities to incorporate into their existing infrastructures. Because value-based health care initiatives have bipartisan support, it is likely that these programs will continue to play a major role in both the public and private health insurance systems. As such, there is a pressing need to evaluate the implementation of these initiatives thus far and to discuss the direction that American health care financing will take in the coming years.
To explore this important issue, the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School collaborated with Ropes & Gray LLP to host a one-day conference on value-based health care. This event brought together scholars, health law practitioners, and health care entities to evaluate the impact of value-based health care on the American health care system.
For more information, visit our website at: http://petrieflom.law.harvard.edu/events/details/will-value-based-care-save-the-health-care-system
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Takeaways from a roundtable held on June 1st about patient-centred pharmacare in Canada
● Reports from patient groups and other subject matter experts
● A cohesive vision and set of values for national pharmacare in Canada
View the video: https://youtu.be/HMy_gsTDkfI
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
Decision aids help patients and clinicians decide on the best course of treatment, incorporating evidence from systematic reviews, patient values, individual risk factors, and expert recommendations, all in an intuitive and interactive format.
Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...Sardegna Ricerche
L'intervento di Luca Pani (professore Ordinario di Psichiatria Clinica, Università di Miami) in occasione dell'evento "Il valore della ricerca biomedica" che si è tenuto a Pula (CA) il 3 aprile 2019.
Are you a physician, innovator, or entrepreneur with a commercial idea and ready to make it a fundable company? Join us for this full-day program to understand today’s unique challenges for life science, med device, and healthcare entrepreneurs starting companies and raising capital. Learn from and meet some of the leading life science investors, entrepreneurs, and early-stage experts in New England.
Building on the success of The Capital Network’s annual Fast Track Boot Camp for Entrepreneurs, this Life Science Fast Track is an intensive, interactive full-day seminar designed to provide entrepreneurs and innovators an in-depth understanding of what it takes to raise early stage capital for a life science startup.
HAS 20 Virtual: Featuring a World-Class Lineup of Keynote SpeakersHealth Catalyst
The Healthcare Analytics Summit (HAS®) is going virtual this year but will still feature the same world-class experience you expect from HAS–including world-class keynote speakers. HAS 20 Virtual will showcase well-known visionaries and C-level executives from leading healthcare organizations. The summit will feature speakers who’ve battled COVID-19 in the trenches as well as other speakers adjusting to planning for the “new normal” that we all anticipate.
We’re reimagining HAS 20 in a virtual format that will be unlike any other healthcare conference you may have attended, virtual or otherwise. HAS 20 Virtual takes place September 1-3, 2020 and will feature nationally recognized keynote speakers, educational breakout sessions, and much more.
pharmacogenomics, current regulatory efforts to ensure and promote innovationscomplianceonline123
It covers the new and expected regulations and their effects on use of pharmacogenomics in industry. PharmacoGenomics Data, genetic tests and Biomarkers, FDA guidances and federal initiatives, EMEA, Clinical Genomics data standards will explore medicine landscape.
The World Organization of Natural Medicine is an international politically and religiously neutral humanitarian none governmental organization (NGO). It is established as per the World Health Organization Alma Ata declaration 1978, and is recognized and accredited under the Sovereigns Order of Knight Hospitallers of St. John for its humanitarian endeavors. Its educational department is a member of the United Nation Academic Impact.
About the Webinar: Michelle Colero, Executive Director of Bladder Cancer Canada, will cover the essentials of bladder cancer facts and symptoms while also outlining the support and educational resources provided by Bladder Cancer Canada for those dealing with a diagnosis. Additionally, she’ll share ways individuals can contribute to raising awareness and supporting our community.
About the Webinar: Alcohol is classified as a Group one carcinogen and is estimated to be one of the top three causes of cancer deaths worldwide. Yet, over 40 per cent of people in Canada remain unaware that alcohol consumption increases the risk of developing at least nine cancers. In this presentation, we’ll look at what is and isn’t known about the relationship between alcohol and cancer. We’ll explore what the Canadian Cancer Society is doing to raise awareness of alcohol as a modifiable cancer risk factor, its commitment to funding world-leading research on this subject, and its advocacy for stronger policies that reduce, and increase awareness about the risk of cancer related to, alcohol consumption. Attendees will be invited to seek more information and/or take action on this important topic. We hope you’ll join us in learning more about cancer risk and alcohol — the most commonly used psychoactive substance in Canada.
Dr. Rob Rutledge returns for his first webinar of 2024 to discuss the basics behind emotional intelligence. Learn how to develop greater emotional awareness, and learn how to settle fear and frustration. Dr. Rutledge will also share tips on how to live in a more peaceful and connected way as you navigate through your cancer journey.
About the Webinar: Health technology assessment (HTA), the approval process for drugs and healthcare technology, the processes and organizations that support them, such as Canadian Agency for Drugs and Technologies in Health (CADTH), have evolved over the years in response to changing healthcare system priorities and the need to establish their legitimacy. Don Husereau will provide an overview of current processes in Canada, and highlight their perceived (and real) shortcomings and what can be done to overcome these. He will highlight that some perceived weaknesses (such as review times) are not as bad as they appear while perceived strengths (such as stakeholder involvement) need considerable improvement. He will also discuss other opportunities for HTA to innovate and whether there are current plans to address these.
About this Webinar: The time between regulatory approval for new drugs and when drugs became publicly available to patients averaged 736 days (25 months) in 2022. This is double the average time reported in comparable Organisation for Economic Development (OECD) countries. This webinar will highlight variations in drug listing time for new drugs across time, provinces, and type of drugs (oncology vs. non-oncology). It will also present the specific phases involved in moving a drug from approval stage to listing, and the time spent in each. This Conference Board of Canada analysis uses IQVIA’s Market Access Metrics Database (2012 to 2023), which tracks all new products and their indications through the Canadian access journey.
About the Webinar: Learn about pancreatic cancer symptoms, diagnosis, treatment options, statistics, supports and barriers. The presentation will also include some helpful tools that can improve quality of life for those with pancreatic cancer, including the Craig's Cause's PERT (Pancreatic Enzyme Replacement Therapy) calculator and available patient support programs.
As referenced by John Adams in his 2024 CCSN Webinar on the US importing drugs from Canada, this is a slide deck from Health Canada which outlines the timetable and actions taken by the government on this particular issue.
About this Webinar: John Adams takes a dive behind the headlines, news stories and media releases to better understand any real threats to Canadian patients getting the prescription drugs they need.
About this Webinar: We know that methods of eating and diet are a large part of cancer care, but how can you make your diet work for you in your cancer journey? Dr. Rob Rutelege is back to present the latest science around healthy eating and cancer care. In addition, Dr. Rutledge will share the benefits of time-restricted eating, and how you can incorporate it into your daily routine.
Colorectal cancer is the second leading cause of cancer death in Canada, with approximately 24,100 Canadians diagnosed with the disease in 2023. The incidence of colorectal cancer has been declining in Canadians over 50 years of age, largely due to population-based screening programs. Recent evidence has shown, however, that rates have been increasing in adults younger than 50 years. Given that younger adults are typically classified as at low risk for colorectal cancer, this epidemiologic shift is cause for concern.
Individuals under the age of 50 now represent a significant number of colorectal cancer cases. The disease is often being diagnosed at a later stage, and tumour characteristics tend to be more lethal. As for what is accounting for the increasing trend, ongoing research efforts focus on environmental toxicities, lifestyle patterns, and the gut microbiome.
In this webinar, we will present an overview of the current evidence surrounding the rising rates of colorectal cancer in young adults and discuss the unique needs of this patient population, through screening, diagnosis, treatment, and survivorship. A young colorectal cancer patient will share his lived experience in managing this disease and the impact that cancer has had on himself and his family.
About this Talk: This talk will provide a nutritional perspective on the role of diet in cancer focusing on healthy fats known as omega-3 fatty acids. Sources, amounts and types of omega-3 fatty acids will be highlighted. Clinical and experimental evidence in support of a role for omega-3 fatty acids in the prevention and treatment of breast cancer will be presented. Lastly, some practical strategies to support a healthy diet will be shared.
About the Webinar: Genomic testing has already become commonplace in oncology, but exponential growth in more comprehensive genomic tests, other innovative tests and testing approaches in oncology, as well as a number of other therapeutic areas is expected in the coming years. With the emergence of more complex, more expensive, and more promising tests, policymakers and healthcare providers may be challenged to provide these to patients at the pace of innovation. Don Husereau will describe what conditions are necessary for equitable access to advanced innovative testing, how major Canadian provinces are doing, and what more needs to be done in the coming years to benefit all patients.
About this Webinar: This talk will explore breast screening for women 40-49. The benefits and harms for screening will be discussed, as well as what is unique about breast cancer in women in their 40s. In order to understand the controversy around current guidelines recommending against screening women 40-49, we will review the evidence upon which these guidelines are based, and their impact on breast cancer outcomes for these women.
About this Webinar: This presentation will discuss the pathway to pharmaceutical treatments in Canada that involve health technology assessment reviews and decision making. Observations on the current challenges and the importance of patient input to inform decision making will also be discussed. Finally, the key elements that can be critical to successful outcomes will be presented.
About this Webinar: When Canadians turn on the tap for a drink of water or a shower, we take for granted that the water is safe. Few are aware that old asbestos cement water pipes still deliver water to millions of people. As these pipes age and deteriorate, asbestos erodes into the water and poses health concerns, including cancer.
Dr. Meg Sears, Chair of the Board of Prevent Cancer Now, and board member Julian Branch will talk about the history of asbestos in water, the science behind ingested asbestos, and recent developments.
André Deschamps will show the results of the Europa UOMO Euproms studies. These are the first studies ever from patients for patients, measuring the burden of treatment. More than 5000 patients have shared with us their experiences after treatment. The data has been analyzed by the university of Rotterdam in the Netherlands and has been published in peer reviewed scientific papers.
This webinar will serve as an introduction to Cancer and Work, a website that “was designed to address the unique needs of cancer survivors with returning, remaining, changing work or looking for work after a diagnosis of cancer. The website provides newly created information, resources, and interactive tools for cancer survivors, healthcare providers, employers, and highlights helpful information from across the globe.” The talk will include 10 steps to return to work, and job search ideas for cancer survivors
This webinar will have two perspectives.
Jasveen will be presenting about the impact of cancer and treatment on a person’s physical, cognitive & mental health and how an Occupational therapist can work with the person to gradually overcome these challenges to return to work with or without modifications. The presentation will cover some case studies of past success with the opportunity to answer questions at the end.
Then we will hear from Jen who has experienced her own journey with breast cancer and how she advocated for herself and occupational therapy to help her return to full time employment.
About this Webinar: we’ll summarize the findings of a 10-minute online study conducted by Leger among cancer patients who experienced Long-COVID. We identified 119 cancer patients, diagnosed within the past 10 years, who developed symptoms or were diagnosed with Long-COVID. We primarily wanted to understand how Long-COVID impacted cancer patients and their ability to receive treatment. We also asked about the effect on their overall wellbeing, their ability to access Long-COVID treatments and assistance, and the ongoing impact to this day.
About this Presenter: Colette Faust is a Research Director at Leger (largest Canadian-owned market research company) and has 10 years of market research experience, spending the last 3 years in the healthcare industry. As a member of Leger’s North American Healthcare team, Colette has worked on both quantitative and qualitative healthcare research among healthcare professionals, patients, and the general population across a variety of topics including oncology. Colette received her B.A. in Psychology and Media & Communications from Muhlenberg College in Allentown, PA.
Various cancer treatments can impact one’s gut health and digestive system. This presentation will discuss why a healthy gut is important to overall health. We will talk about the roles the gut is involved in beyond just digestion. We will also discuss nutrition strategies that will support our gut health and promote a healthy microbiome.
Russian anarchist and anti-war movement in the third year of full-scale warAntti Rautiainen
Anarchist group ANA Regensburg hosted my online-presentation on 16th of May 2024, in which I discussed tactics of anti-war activism in Russia, and reasons why the anti-war movement has not been able to make an impact to change the course of events yet. Cases of anarchists repressed for anti-war activities are presented, as well as strategies of support for political prisoners, and modest successes in supporting their struggles.
Thumbnail picture is by MediaZona, you may read their report on anti-war arson attacks in Russia here: https://en.zona.media/article/2022/10/13/burn-map
Links:
Autonomous Action
http://Avtonom.org
Anarchist Black Cross Moscow
http://Avtonom.org/abc
Solidarity Zone
https://t.me/solidarity_zone
Memorial
https://memopzk.org/, https://t.me/pzk_memorial
OVD-Info
https://en.ovdinfo.org/antiwar-ovd-info-guide
RosUznik
https://rosuznik.org/
Uznik Online
http://uznikonline.tilda.ws/
Russian Reader
https://therussianreader.com/
ABC Irkutsk
https://abc38.noblogs.org/
Send mail to prisoners from abroad:
http://Prisonmail.online
YouTube: https://youtu.be/c5nSOdU48O8
Spotify: https://podcasters.spotify.com/pod/show/libertarianlifecoach/episodes/Russian-anarchist-and-anti-war-movement-in-the-third-year-of-full-scale-war-e2k8ai4
A process server is a authorized person for delivering legal documents, such as summons, complaints, subpoenas, and other court papers, to peoples involved in legal proceedings.
Presentation by Jared Jageler, David Adler, Noelia Duchovny, and Evan Herrnstadt, analysts in CBO’s Microeconomic Studies and Health Analysis Divisions, at the Association of Environmental and Resource Economists Summer Conference.
ZGB - The Role of Generative AI in Government transformation.pdfSaeed Al Dhaheri
This keynote was presented during the the 7th edition of the UAE Hackathon 2024. It highlights the role of AI and Generative AI in addressing government transformation to achieve zero government bureaucracy
Jennifer Schaus and Associates hosts a complimentary webinar series on The FAR in 2024. Join the webinars on Wednesdays and Fridays at noon, eastern.
Recordings are on YouTube and the company website.
https://www.youtube.com/@jenniferschaus/videos
What is the point of small housing associations.pptxPaul Smith
Given the small scale of housing associations and their relative high cost per home what is the point of them and how do we justify their continued existance
This session provides a comprehensive overview of the latest updates to the Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (commonly known as the Uniform Guidance) outlined in the 2 CFR 200.
With a focus on the 2024 revisions issued by the Office of Management and Budget (OMB), participants will gain insight into the key changes affecting federal grant recipients. The session will delve into critical regulatory updates, providing attendees with the knowledge and tools necessary to navigate and comply with the evolving landscape of federal grant management.
Learning Objectives:
- Understand the rationale behind the 2024 updates to the Uniform Guidance outlined in 2 CFR 200, and their implications for federal grant recipients.
- Identify the key changes and revisions introduced by the Office of Management and Budget (OMB) in the 2024 edition of 2 CFR 200.
- Gain proficiency in applying the updated regulations to ensure compliance with federal grant requirements and avoid potential audit findings.
- Develop strategies for effectively implementing the new guidelines within the grant management processes of their respective organizations, fostering efficiency and accountability in federal grant administration.
1. Panelist Bios:
Glen Doucet
Mr. Glen Doucet has been Vice President of Advocacy at Canadian Pharmacists
Association (CPHA) since October 27, 2014. Mr. Doucet is a government relations and
public affairs expert with more than 23 years of experience working in political,
governmental and non-governmental organizations. Prior to his most recent role as
Executive Director for the Fur Institute of Canada, he spent four years as the Vice
President, Government Relations & Public Affairs with the Canadian Diabetes
Association and 10 years with the Government Relations group at the Canadian
Medical Association.
Louise Binder
Louise Binder is a lawyer and health advocate who has been involved in informing the
development of health policy and systemic treatment access practices from a patient
perspective for more than 20 years. She started her work in this area in the HIV
community in the early 1990s after her own diagnosis and before effective treatments
were available for HIV. She co-founded the Canadian Treatment Action Council (CTAC)
in 1996, which successfully ensured access to treatments and quality care for people
living with HIV by working with the federal and provincial governments and other
relevant stakeholders to enhance drug review and approval systems, pricing policies
and access to liver transplants for this community. She wrote a paper on universal drug
coverage a decade ago while chair of CTAC. She had a special interest in women's
issues, chairing the Ontario women's organization Voice of Positive Women for more
than a decade, and has been involved in these issues internationally as well. Two years
ago, Louise began similar work in the cancer area and is presently health policy
consultant for the Canadian Cancer Survivor Network. She has been recognized by
many organizations for her work, including receiving an Honorary Doctorate of Laws
from her alma mater, Queen's Law School; the Order of Ontario from the Province of
Ontario; and two Queen Elizabeth II medals.
Marc-André Gagnon
Associate Professor with Carleton University’s School of Public Policy and
Administration. He holds a PhD in Political Science from York University and a Master’s
of Advanced Study in Economics from Paris-1 Sorbonne and École Normale Supérieure
de Fontenay/St-Cloud. He did his post-doctoral training with the Centre for Intellectual
Property Policy at McGill University’s Faculty of Law, and with the Edmond J. Safra
Center for Ethics at Harvard University. His current research focuses mainly on the
political economy of the pharmaceutical sector. He analyzes institutional corruption in
the pharmaceutical sector, regulatory capture of public institutions, innovation policies
and intellectual property in the knowledge-based economy, as well as comparative
regimes of health insurance and Pharmacare. He is currently Fellow with the WHO
Collaborating Centre for Governance, Accountability and Transparency in the
Pharmaceutical Sector, and researcher with the Rational Therapeutics and Medication
Policy research group.
2. Don Husereau
Don Husereau is an Adjunct Professor of Medicine at The University of Ottawa, Senior
Associate with the Institute of Health Economics, and Senior Scientist at the University
for Health Sciences, Medical Informatics and Technology in Hall in Tirol, Austria. Don’s
current research focuses on appropriate and innovative approaches to the use of
evidence and economics to inform health policy based on sound principles of social
justice, epistemology, and judgment and decision-making. He is currently Chair of an
International Task Force that has developed consolidated health economic evaluation
reporting standards (CHEERS) that is now endorsed by leading biomedical and health
policy journals. Don is currently an Editorial Advisor for the biomedical journals, Value in
Health and BMC Medicine. He also serves on the pan-Canadian Oncology Drug Review
(pCODR) Expert Review Committee (pERC) and Ontario Committee to Evaluate Drugs.
Don received both his BSc and MSc from the University of Alberta's faculty of Pharmacy
and Pharmaceutical Sciences.
W. Neil Palmer
President and Principal Consultant of PDCI Market Access Inc (PDCI) a leading pricing
and reimbursement consultancy founded) in 1996. At PDCI, he leads a senior team of
market access professionals with pricing & reimbursement engagements focusing
primarily on the Canadian market. Neil is also Adjunct Assistant Professor at the
University of Southern California School of Pharmacy graduate program in Health Care
Decision Analysis where he lectures on health technology assessment, pricing and
market access from a global perspective. Neil served as global vice president for pricing
and reimbursement with RTI Health Solutions of RTP North Carolina from 2006 – 2009.
He previously worked with the Canadian Patented Medicine Prices Review Board
(PMPRB), the Health Division of Statistics Canada and the research group of the
Kellogg Centre for Advanced Studies in Primary Care in Montreal. A graduate of the
University of Western Ontario, Neil has written extensively on pharmaceutical pricing
and reimbursement issues and is a frequent speaker at conferences in North America
and Europe.